Aug 07, 2020 / 12:45PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporate 2020 Second Quarter Financial Results and Corporate Update Conference Call.
(Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would like to hand the conference over to one of your speakers today, Ms. Pam Murphy. Ma'am, please go ahead.
Pam Murphy - Arbutus Biopharma Corporation - IR Consultant
Good morning, and thank you for joining Arbutus' Q2 2020 Conference Call. On the call from the Arbutus Executive team are Bill Collier, President and Chief Executive Officer; Dr. Mike Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and Dave Hastings, Chief Financial Officer.
Bill will begin with a summary of recent accomplishments and a review of Arbutus' corporate objective, followed by Gaston and Mike Sofia, who will provide you with updates on the clinical development of AB-729, Arbutus' early-stage HBV program -- pipeline and its COVID-19 research efforts
Q2 2020 Arbutus Biopharma Corp Earnings Call Transcript
Aug 07, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers